Answer
Breastfeeding should be avoided during treatment with Korserdu (elacestrant dihydrochloride) and for one week after the last dose because of potential serious adverse reactions in the breastfed infant.
Sources for this answer
- Korserdu (elacestrant) 345mg film-coated tabletsMenarini Stemline UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 3Document updated
Sources checked